FIL Ltd increased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 13.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 729,275 shares of the biotechnology company's stock after purchasing an additional 89,016 shares during the quarter. FIL Ltd owned approximately 1.20% of Ascendis Pharma A/S worth $100,399,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth about $30,000. Jones Financial Companies Lllp boosted its position in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Blue Trust Inc. boosted its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares during the last quarter. GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $203,000.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on ASND shares. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a report on Tuesday, February 18th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and a consensus target price of $204.64.
Get Our Latest Stock Report on Ascendis Pharma A/S
Ascendis Pharma A/S Trading Down 0.9 %
ASND stock traded down $1.35 during trading on Tuesday, reaching $154.15. 101,772 shares of the stock were exchanged, compared to its average volume of 477,472. The firm's 50 day moving average is $148.85 and its 200 day moving average is $137.71. The firm has a market cap of $9.40 billion, a P/E ratio of -21.71 and a beta of 0.54. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $169.37.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. As a group, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.
About Ascendis Pharma A/S
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
